TY - JOUR
T1 - EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARSCoV-2
T2 - the November 2021 update
AU - Landewé, Robert B.M.
AU - Kroon, Féline P.B.
AU - Alunno, Alessia
AU - Najm, Aurélie
AU - Bijlsma, Johannes W.J.
AU - Burmester, Gerd Rüdiger R.
AU - Caporali, Roberto
AU - Combe, Bernard
AU - Conway, Richard
AU - Curtis, Jeffrey R.
AU - Elkayam, Ori
AU - Gossec, Laure
AU - Heijstek, Marloes W.
AU - Haupt, Lukas
AU - Iagnocco, Annamaria
AU - Isaacs, John D.
AU - Juhász, István Ábel
AU - Makri, Suzi
AU - Mariette, Xavier
AU - McInnes, Iain B.
AU - Mehta, Puja
AU - Mueller-Ladner, Ulf
AU - Schulze-Koops, Hendrik
AU - Smolen, Josef S.
AU - Wiek, Dieter
AU - Winthrop, Kevin L.
AU - Navarro-Compán, Victoria
AU - Machado, Pedro M.
N1 - Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR’s standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.
AB - The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR’s standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.
UR - http://www.scopus.com/inward/record.url?scp=85127879022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127879022&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2021-222006
DO - 10.1136/annrheumdis-2021-222006
M3 - Article
C2 - 35197264
AN - SCOPUS:85127879022
SN - 0003-4967
VL - 81
SP - 1628
EP - 1639
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 12
ER -